We will be working with NHS and NIHR with a patented prescription technology.

We have a UK Network of ‘Best Practice’ medical centres where specialists can prescribe or oversee prescriptions of Medicinal Cannabis.

Medicaleaf™ intends to generate revenue in excess of £5.34 million in this first trading year.

Annual predicted net profit over sales metric of ‘plus 43%’.

Medicaleaf™ will have a ‘post-raise’ valuation of £20 million with expectations to reach a pre-floatation valuation of £200 million in three years’ time.

Offset over 50% of your investment with CGT and EIS relief.

Invest in the future of the NHS

EIS Advance Assurance from HMRC

Earn 43% returns per annum

Enter your details below to request more information 

DISCLAIMER:
The information provided on this website is for information purposes only. The website and its content are not, and should not be deemed to be an offer of, or invitation to engage in any investment activity. The website should not be construed as advice, or a personal recommendation by Medicaleaf Ltd . Medicaleaf Ltd  is not authorised and regulated by the Financial Conduct Authority (FCA). The content of this promotion is not authorised under the Financial Services and Markets Act 2000 (FSMA). Reliance on the promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the investment. UK residents wishing to participate in this promotion must fall into the category of sophisticated investor or high net worth individual as outlined by the Financial Conduct Authority (FCA).